Xilio Therapeutics to present preclinical data on CLDN18.2 therapy at AACR

March 17, 2026 4:45 PM

Xilio Therapeutics, Inc. (NASDAQ: XLO) will present preclinical data for its masked T cell engager program targeting CLDN18.2 at the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found